PET-guided radiation for high-risk meningiomas
Part of Brain & nervous system, Cancer clinical trials.
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have a grade 3 meningioma (any type) OR a grade 2 meningioma that came back OR a first-time grade 2 meningioma with leftover tumor after surgery.
- If your tumor came back, your doctor can confirm it by a scan or a biopsy.
- You have not had radiation to the brain before.
- You are well enough to be up and about (ECOG score 0-2).
- You are able to have an MRI and a PET scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a higher dose of proton therapy, a precise type of radiation, can better control a rare and more aggressive form of meningioma brain tumor. It aims to improve outcomes for patients who have had surgery and need radiation.
This study uses a special PET scan (DOTATATE) to help doctors plan radiation treatment for meningioma, a type of brain tumor. The scan may help target radiation more precisely, potentially improving outcomes.
This study tests a type of focused radiation therapy (called stereotactic radiosurgery) given after surgery for certain meningiomas. The goal is to see if this treatment helps prevent the tumor from coming back, and to check its safety.
This study uses a special PET scan to see if your recurrent meningioma has a protein called PSMA. This could help decide if a new treatment that targets this protein might work for you.
This study compares different radiation methods for treating a slow-growing, non-cancerous brain tumor at the base of the skull. It aims to see which approach best protects memory and thinking abilities.
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.